
|Articles|November 1, 2003
REGIMEN FOR SKIN INFECTIONS
New data suggest InterMune Inc.'s intravenous oritavancin is as effective as a regimen of vancomycin plus cephalexin in treating patients with complicated skin and skin-structure infections (CSSSI).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study
3
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
4
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
5














